Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

- Roche, a world leader in integrated Personalised Diabetes Management, and the Zur Rose Group, provider of the European digital healthcare ecosystem, announce their collaboration to improve everyday therapy management and better address the needs of 60 million people living with diabetes in Europe [1]

- The collaboration will empower people with diabetes to self-manage their condition for a better quality of life and enable healthcare professionals to efficiently provide optimal and integrated care

Today, Roche and the Zur Rose Group announce a collaboration to empower people with diabetes and their caregivers in their daily therapy management. In Europe, there are 60 million people living with diabetes, i.e. approximately 9 per cent of the population older than 20 years [1]. The prevalence of diabetes is rising among all ages and in particular of type 2 diabetes, which is mostly due to decreases in physical activity and an unhealthy diet. It is becoming one of the major healthcare issues for society across the globe [2].

As part of the collaboration, Roche Diabetes Care and the Zur Rose Group are connecting their healthcare products and solutions and those of best-in-class third parties to improve the lives of people with diabetes. Customers will benefit from an integrated shared offering, including convenient access to self-management solutions, telemedicine services, scripts and refills, diabetes management supplies and devices, data visualisation and decision support tools. This offering will become available in Germany as a first market in 2022 and is foreseen to be expanded to other European markets. It will focus primarily on people living with type 2 diabetes, which accounts for about 90 per cent of all cases [1].

As a global leader in integrated Personalised Diabetes Management, Roche Diabetes Care aims to drive sustainable care to improve the lives of people with diabetes. The company connects its own devices and digital solutions, such as one of the world's most popular diabetes management apps mySugr, and third-party devices and services in an open ecosystem. Through the contextualisation of relevant data, this enables deeper insights and a better understanding of the disease, leading to more personalised and effective therapy management.

With its pharmaceutical experts, eHealth and pharmacy platforms, telemedicine and technology expertise, and consumer reach, the Zur Rose Group will bring convenient and personalised diabetes journeys to life seamlessly connecting health products and solutions. This will also enable healthcare practitioners to be in touch with people with diabetes when and where needed. This new ecosystem under the DocMorris umbrella brand for consumer-centric diabetes management will include assets of both companies as well as other best-in-class third-party solutions and service providers.

"In our efforts to bring true relief to people with diabetes and their caregivers, we are excited to partner with the Zur Rose Group to complement our offerings. We see great potential in this collaboration to simplify daily self-management for people with diabetes. It will enable us to provide even more personalised and holistic therapy support to people with diabetes thus lowering the everyday burden of this chronic disease", says Marcel Gmünder, Global Head of Roche Diabetes Care.

"People living with diabetes are requesting access to high-quality care and innovative solutions that simply integrate into their lives and improve their quality of life," adds Walter Oberhänsli, CEO of the Zur Rose Group. "We are delighted to join forces with Roche Diabetes Care combining our healthcare expertise and digital assets within our ecosystem, empowering people with diabetes with a personalised and comprehensive health journey - all in one click."

[1] IDF Diabetes Atlas, 9th edition, 2019
[2] https://www.who.int/health-topics/diabetes#tab=tab_1

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 4

Media contacts
Zur Rose Group:
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Segment Germany of the Zur Rose Group:
Torben Bonnke, Director Communication & PR
Email: torben.bonnke@docmorris.de, phone +49 30 21222 36 12

eHealthcare ecosystem contact
Betül Susamis Unaran, Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com, phone +41 79 834 41 40

Agenda
20 January 2022 Sales 2021
24 March 2022 2021 Full-Year Results
20 April 2022 First Quarter Trading Update
28 April 2022 Annual General Meeting

About the Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 1,752 million in 2020.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.